Courtesy of Benzinga.
Oncolytics Biotech (NASDAQ: ONCY) today announced final tumour response data from
its U.S. Phase 2 single arm clinical trial in patients with squamous
cell carcinoma of the lung (SCCLC) using intravenous administration of
REOLYSIN in combination with carboplatin and paclitaxel (REO 021).
The analysis examined percent best overall tumour responses between
pre-treatment and up to six treatment cycles. Of 25 evaluable patients
who had more than one cycle of therapy, 23 (92%) exhibited overall
tumour shrinkage (mean shrinkage was 32.7%). Of the 25 evaluable
patients, 10 (40%) had partial responses (PRs), while a further 13
(52%) showed stable disease (SD) and two (8%), had progressive disease
(PD), for a disease control rate (complete response (CR) + PR + SD) of
92%. A waterfall graph showing individual patient data will be
available on the Company’s website at http://www.oncolyticsbiotech.com/presentations.
“We are thrilled to have demonstrated 92% overall tumour shrinkage in
this group of patients,” said Dr. Brad Thompson, President and CEO of
Oncolytics. “Squamous cell carcinoma of the lung is notoriously
difficult to treat, and these results support further investigation of
REOLYSIN in randomized clinical trials for this indication.”
The study enrolled patients with metastatic stage
